【摘要】 肝细胞癌(HCC)是当今社会最常见的恶性肿瘤之一。手术切除仍是目前主要的治疗方法，但术后存在死亡率高、预后差等问题，因此寻求更加安全、高效的治疗策略尤为重要。肿瘤坏死因子相关凋亡诱导配体(TRAIL)是肿瘤坏死因子(TNF)家族的新成员之一，相关受体在治疗肿瘤方面具有良好的优势，是具有抗肿瘤作用的潜在靶点。近年来，基于TRAIL受体激动剂及其联合治疗策略已经投入临床HCC的治疗，并取得了不错的临床治疗预期。但随着HCC耐药的发展，针对现有机制的TRAIL受体激动剂似乎难以达到预期效果，因此深入探寻HCC耐药机制及其新的联合治疗策略，对于HCC治疗十分必要。本文主要对TRAIL在发挥治疗HCC中涉及的相关机制尤其是相关耐药机制以及近年临床上使用的TRAIL受体激动剂联合用药策略进行综述。更多还原

【Abstract】 Hepatocellular carcinoma(HCC) is one of the most common malignant tumor in the society today. Surgical resection is currently the main treatment method, but there are problems with high mortality and poor prognosis after surgery. Therefore it is particularly important to seek more safe and efficient treatment strategies. TNF-related apoptosis inducing ligand(TRAIL) is a new member of the tumor necrosis factor(TNF) family. The related receptors for TRAIL have good advantages in treating tumors, which might be potential target with anti-tumor effects. In recent years, TRAIL-based receptor agonists and their combination therapy strategies have been put into clinical treatment against HCC and have achieved good clinical treatment expectations. However, with the development of HCC drug resistance, TRAIL receptor agonists targeting the existing mechanism seem to be difficult to achieve the expected effects. So it is necessary for HCC treatment to further explore the mechanism of HCC drug resistance and new combination therapy strategies. This article summarizes the relevant mechanisms especially for drug resistance mechanisms involved in the use of TRAIL in the treatment of HCC, as well as the combined use of TRAIL receptor agonists in clinic in recent years.更多还原